The successful immune response against hepatitis C nonstructural protein 5A (NS5A) requires heterologous DNA/protein immunization (Q39734465)

14 September 2017

The successful immune response against hepatitis C nonstructural protein 5A (NS5A) requires heterologous DNA/protein immunization (English)

1 reference

14 September 2017

Olga V Masalova

1

1 reference

14 September 2017

Ekaterina I Lesnova

2

1 reference

14 September 2017

Alexei V Pichugin

3

1 reference

14 September 2017

Tatiana M Melnikova

4

1 reference

14 September 2017

Vadim V Grabovetsky

5

1 reference

14 September 2017

Natalia V Petrakova

6

1 reference

14 September 2017

Olga A Smirnova

7

1 reference

14 September 2017

Alexander V Ivanov

8

1 reference

14 September 2017

Alexei D Zaberezhny

9

1 reference

14 September 2017

Ravshan I Ataullakhanov

10

1 reference

14 September 2017

Maria G Isaguliants

11

1 reference

14 September 2017

Alla A Kushch

12

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

14 September 2017

1 reference

14 September 2017

28

1 reference

14 September 2017

8

1 reference

14 September 2017

1987-1996

1 reference

Adaptive immune responses in acute and chronic hepatitis C virus infection

14 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Neutralizing antibodies in hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Cellular immune selection with hepatitis C virus persistence in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

A small step closer to the Holy Grail of DNA vaccines: undisputed clinical benefit in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Induction of immune responses by DNA vaccines in large animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

DNA vaccines: developing new strategies to enhance immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Chemical adjuvants for plasmid DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Development of nonhuman adenoviruses as vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

DNA vaccine strategies: candidates for immune modulation and immunization regimens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Immunogenicity of DNA vaccines in humans: it takes two to tango

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

DNA vaccination against tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Hepatitis C virus NS5A: tales of a promiscuous protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Structural biology of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Hepatitis C virus NS5A protein modulates template selection by the RNA polymerase in in vitro system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Interaction of Hepatitis C Virus Nonstructural Protein 5A with Core Protein Is Critical for the Production of Infectious Virus Particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Hepatitis C virus-host interactions: the NS5A protein and the interferon/chemokine systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

1Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

NS5A--from obscurity to new target for HCV therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Intracellular accumulation of hepatitis C virus proteins in a human hepatoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Prospects for a vaccine against the hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

DNA vaccines for biodefence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Comparison of antibody- and cell-mediated immune responses after intramuscular hepatitis C immunizations of BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Strategies for loading dendritic cells with hepatitis C NS5a antigen and inducing protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Development of a hepatitis C virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Development of prophylactic and therapeutic vaccines against hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Immunotherapy for HCV infection: next steps.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.097

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.10.097

1 reference

14 September 2017

1 reference